Scotia

Article Abstract:

Scotia is active in lipid biology, obesity, drug delivery and cancer therapies. The company's biggest stockholder is Perpetual, which has acquired over 5 million stocks from the founder, David Horrobin, who has ceased to be chief executive. The company's product, Foscan, is in advanced stages of trials. The company has also signed an agreement with General Foods for its anti-obesity product, Olibra, and progress is reportedly being made in its drug delivery operations.

Scotia Holdings PLC

---

Miracle drugs, mega profits

Article Abstract:

The rapid progress being made in medical research means that many firms are now developing wonder-drugs which could transform the companies and make them huge profits. Promising areas include central nervous system drugs and stem cell research.

Research, Analysis, Drug therapy, Central nervous system diseases, Pharmaceutical research

---

Bayer reviews pharma strategy

Article Abstract:

Chemicals and pharmaceuticals firm Bayer is to review its drugs strategy, with a joint venture thought to be the most likely outcome. Bayer has been badly hit by deaths linked to its anti-cholesterol drug Baycol.

Bayer AG

Similar abstracts:

• Abstracts: Courtaulds. Threadbare demerger plan. Talent is not enough
• Abstracts: Network wars. Barcrest Group's many games for UK players
• Abstracts: Cordiant bids adieu. Mythical aegis of takeovers
• Abstracts: Costly compliance. Best developed market banks. Getting Back to Basics
• Abstracts: Specialty pharmaceuticals. Drug delivery stocks

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.